NDAINJECTIONINJECTABLE
Approved
Jul 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NICARDIPINE HYDROCHLORIDE (nicardipine hydrochloride) by Hikma is concentrations. First approved in 2008.
Drug data last refreshed 7h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Nicardipine hydrochloride is a calcium channel blocker administered by injection for acute management of cardiovascular disease, particularly hypertension and angina. It selectively inhibits calcium influx into vascular smooth muscle, producing vasodilation with minimal negative inotropic effects on cardiac contractility. The drug is FDA-approved and sponsored by Hikma Pharmaceuticals.
LOE Approaching
Product is approaching loss of exclusivity with minimal commercial momentum, indicating potential team consolidation and shift toward generic management or sunset planning.
Mechanism of Action
concentrations. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. The effects of nicardipine are more selective to vascular smooth muscle than cardiac muscle. In animal…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on nicardipine offers limited career growth given the product's LOE approaching status and minimal linked job activity; roles are defensive in nature, focused on maintaining market share in hospital/acute care settings. Career advancement opportunities are constrained; professionals should view this as a consolidation/efficiency assignment rather than a growth platform.
Brand Manager
Worked on NICARDIPINE HYDROCHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.